Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Sep 02, 2022 11:10am
132 Views
Post# 34938098

RE:RE:RE:RE:RE:All this needs

RE:RE:RE:RE:RE:All this needs
woundedknee wrote: Regardless when the kick off begins..this will be the second phase two of the same drug.


Very true Woundedknee - that is absolutely correct.

But ...

This time it's much higher dosing to start with a taper (likely) - for a very short period.
That's why it likely gets a new patent ... method change.

---------------------

Then, consider how this could be used in chronic ... at higher dose ... reduced frequency ... under close watch of a Specialist.

I'm not say it's going to go there - I'm just saying that I see a potential secondary path.

Maybe that path needs a Phase 2 or maybe there's a faster path once we get acute (if we get acute).  Don't know - yet.

---------------------

I do predict this pause and recent development work ... puts us further ahead in this space.  Lots of work and mucho money to be spent creating a market.  IMO.


<< Previous
Bullboard Posts
Next >>